EMA Recommends Granting a Marketing Authorisation for Catumaxomab By Ogkologos - November 12, 2024 762 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the intraperitoneal treatment of malignant ascites Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Neoadjuvant Treatment with Dual Immune Checkpoint Inhibitors Plus Chemotherapy Produces Numerically... March 23, 2023 Little Girl Declared Cancer-Free For The Holidays Following 2 Years Of... December 24, 2021 What’s at the Root of Ovarian Cancer? New Study May Have... April 24, 2025 Sotorasib in Combination with Panitumumab Results in Longer PFS in Patients... December 6, 2023 Load more HOT NEWS Los ensayos clínicos y las personas mayores, con Dr. Enrique Soto Cancer Research UK report highlights stark cancer inequalities across Scotland Marshall University Study Finds That Walnuts Suppress Breast Cancer Growth And... “The power of science”: HPV vaccine proven to dramatically reduce cervical...
